At some point, in the very near future, recent developments at Neurotrope will explode into the popular press.
In yesterday’s BIO CEO Presentation NTRP telegraphed their expectations for their upcoming P2b results. Dr. Alkon, in his comments, made a clear case for his decades of research into the mechanism and potential treatment of Alzheimer’s disease.
In the end there was no equivocation, no doubts, that they expect success in their P2b trial, with results by the end of April.
The implication for Dr. Alkon and for Neurotrope is vast. The first successful Alzheimer’s disease treatment, in the history of medicine, would transform Neurotrope into a Biotech phenomenon and probably put Dr. Alkon in line for the Noble Prize.
Alzheimer’s and other neurotrophic diseases are a scourge of humankind and of an ageing population.
We wish Neurotrope every success.
Market Data 
Markets 
AI
